PURPOSE: Epigenetic alterations in tissues targeted for cancer play a causal role in carcinogenesis. Changes in DNA methylation in nontarget tissues, specifically peripheral blood, can also affect risk of malignant disease. We sought to identify specific profiles of DNA methylation in peripheral blood that are associated with bladder cancer risk and therefore serve as an epigenetic marker of disease susceptibility. METHODS: We performed genome-wide DNA methylation profiling on participants involved in a population-based incident case-control study of bladder cancer. RESULTS: In a training set of 112 cases and 118 controls, we identified a panel of 9 CpG loci whose profile of DNA methylation was significantly associated with bladder cancer in a masked, independent testing series of 111 cases and 119 controls (P < .0001). Membership in three of the most methylated classes was associated with a 5.2-fold increased risk of bladder cancer (95% CI, 2.8 to 9.7), and a model that included the methylation classification, participant age, sex, smoking status, and family history of bladder cancer was a significant predictor of bladder cancer (area under the curve, 0.76; 95% CI, 0.70 to 0.82). CpG loci associated with bladder cancer and aging had neighboring sequences enriched for transcription-factor binding sites related to immune modulation and forkhead family members. CONCLUSION: These results indicate that profiles of epigenetic states in blood are associated with risk of bladder cancer and signal the potential utility of epigenetic profiles in peripheral blood as novel markers of susceptibility to this and other malignancies.
PURPOSE: Epigenetic alterations in tissues targeted for cancer play a causal role in carcinogenesis. Changes in DNA methylation in nontarget tissues, specifically peripheral blood, can also affect risk of malignant disease. We sought to identify specific profiles of DNA methylation in peripheral blood that are associated with bladder cancer risk and therefore serve as an epigenetic marker of disease susceptibility. METHODS: We performed genome-wide DNA methylation profiling on participants involved in a population-based incident case-control study of bladder cancer. RESULTS: In a training set of 112 cases and 118 controls, we identified a panel of 9 CpG loci whose profile of DNA methylation was significantly associated with bladder cancer in a masked, independent testing series of 111 cases and 119 controls (P < .0001). Membership in three of the most methylated classes was associated with a 5.2-fold increased risk of bladder cancer (95% CI, 2.8 to 9.7), and a model that included the methylation classification, participant age, sex, smoking status, and family history of bladder cancer was a significant predictor of bladder cancer (area under the curve, 0.76; 95% CI, 0.70 to 0.82). CpG loci associated with bladder cancer and aging had neighboring sequences enriched for transcription-factor binding sites related to immune modulation and forkhead family members. CONCLUSION: These results indicate that profiles of epigenetic states in blood are associated with risk of bladder cancer and signal the potential utility of epigenetic profiles in peripheral blood as novel markers of susceptibility to this and other malignancies.
Authors: Kristin Wallace; Karl T Kelsey; Alan Schned; J Steven Morris; Angeline S Andrew; Margaret R Karagas Journal: Cancer Prev Res (Phila) Date: 2009-01
Authors: Xifeng Wu; Yuanqing Ye; Lambertus A Kiemeney; Patrick Sulem; Thorunn Rafnar; Giuseppe Matullo; Daniela Seminara; Teruhiko Yoshida; Norihisa Saeki; Angeline S Andrew; Colin P Dinney; Bogdan Czerniak; Zuo-feng Zhang; Anne E Kiltie; D Timothy Bishop; Paolo Vineis; Stefano Porru; Frank Buntinx; Eliane Kellen; Maurice P Zeegers; Rajiv Kumar; Peter Rudnai; Eugene Gurzau; Kvetoslava Koppova; Jose Ignacio Mayordomo; Manuel Sanchez; Berta Saez; Annika Lindblom; Petra de Verdier; Gunnar Steineck; Gordon B Mills; Alan Schned; Simonetta Guarrera; Silvia Polidoro; Shen-Chih Chang; Jie Lin; David W Chang; Katherine S Hale; Tadeusz Majewski; H Barton Grossman; Steinunn Thorlacius; Unnur Thorsteinsdottir; Katja K H Aben; J Alfred Witjes; Kari Stefansson; Christopher I Amos; Margaret R Karagas; Jian Gu Journal: Nat Genet Date: 2009-08-02 Impact factor: 38.330
Authors: Brock C Christensen; E Andres Houseman; Carmen J Marsit; Shichun Zheng; Margaret R Wrensch; Joseph L Wiemels; Heather H Nelson; Margaret R Karagas; James F Padbury; Raphael Bueno; David J Sugarbaker; Ru-Fang Yeh; John K Wiencke; Karl T Kelsey Journal: PLoS Genet Date: 2009-08-14 Impact factor: 5.917
Authors: Andrew E Teschendorff; Usha Menon; Aleksandra Gentry-Maharaj; Susan J Ramus; Simon A Gayther; Sophia Apostolidou; Allison Jones; Matthias Lechner; Stephan Beck; Ian J Jacobs; Martin Widschwendter Journal: PLoS One Date: 2009-12-18 Impact factor: 3.240
Authors: Dan Wang; Li Yan; Qiang Hu; Lara E Sucheston; Michael J Higgins; Christine B Ambrosone; Candace S Johnson; Dominic J Smiraglia; Song Liu Journal: Bioinformatics Date: 2012-01-16 Impact factor: 6.937
Authors: Scott M Langevin; Devin C Koestler; Brock C Christensen; Rondi A Butler; John K Wiencke; Heather H Nelson; E Andres Houseman; Carmen J Marsit; Karl T Kelsey Journal: Epigenetics Date: 2012-03 Impact factor: 4.528
Authors: Kristina M Jordahl; Amanda I Phipps; Timothy W Randolph; Hilary A Tindle; Simin Liu; Lesley F Tinker; Karl T Kelsey; Emily White; Parveen Bhatti Journal: Epigenetics Date: 2019-06-23 Impact factor: 4.528
Authors: Devin C Koestler; Brock Christensen; Margaret R Karagas; Carmen J Marsit; Scott M Langevin; Karl T Kelsey; John K Wiencke; E Andres Houseman Journal: Epigenetics Date: 2013-06-25 Impact factor: 4.528
Authors: Kristina M Jordahl; Timothy W Randolph; Xiaoling Song; Cassandra L Sather; Lesley F Tinker; Amanda I Phipps; Karl T Kelsey; Emily White; Parveen Bhatti Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-03-14 Impact factor: 4.254